Announcement of The Consolidated Financial Report for The 3rd Quarter of 2026

2026.11.4

Provided by: TTY BIOPHARM COMPANY LIMITED

SEQ_NO	1	Date of announcement	2026/11/04	Time of announcement	17:46:19
Subject	Announcement of The Consolidated Financial Report for The 3rd Quarter of 2026
Date of events	2026/11/04	To which item it meets	paragraph 31
Statement	1.Date of the board of directors submitted or approved:2026/11/04 2.Date of the audit committee approved:2026/11/04 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2026/01/01~2026/09/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD): 5,146,541 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD): 3,015,924 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD): 1,586,033 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD): 1,803,360 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD): 1,475,037 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD): 1,355,651 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD): 5.45 11.Total assets end of the period (thousand NTD): 12,242,370 12.Total liabilities end of the period (thousand NTD): 3,916,574 13.Equity attributable to owners of parent end of the period (thousand NTD): 7,465,387 14.Any other matters that need to be specified:None.